newsfilter
← Latest News
GlobeNewswire·

Immunomedics Reports Second Quarter 2020 Results and Provides Corporate Update

Encouraging early adoption of Trodelvy™ in U.S. with $20.1M net sales in first two months of launch Confirmatory Phase 3 ASCENT study met primary endpoint of progression-free survival and key...